Mitigating False Negatives And Pneumothorax During FNA

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Although universally acknowledged as a safe minimally invasive procedure, FNA demands unwavering vigilance regarding Quality Control (QC) and complication prevention-principles that must permeate every phase of the process.

False-negative results constitute the foremost QC challenge. A false negative occurs when malignancy exists, yet cytology erroneously reports benign findings. Etiologies are multifactorial: Sampling error​ arises if the fine needle misses the tumor epicenter or fails to engage a small (<1 cm) lesion. Interpretive error​ stems from insufficient cytological expertise, misclassifying atypical cells as reactive or overlooking the subtle features of rare malignancies. Processing error​ involves overly thick smears or delayed fixation, compromising cellular morphology. To mitigate these risks, the "multi-pass" principle is strongly endorsed-performing at least 3–6 aspirations from various angles to ensure representative sampling. Furthermore, implementing ROSE allows cytopathologists to immediately assess specimen adequacy on-site. Unsatisfactory samples trigger immediate repeat passes, a practice proven to slash false-negative rates to below 5%.

Complication prevention focuses primarily on hemorrhage and, rarely, pneumothorax. Due to the fine caliber and gentle technique, significant bleeding or hematoma is uncommon (<1% incidence). Nevertheless, caution is warranted in patients with coagulopathies or those on anticoagulant therapy, where FNA may be contraindicated. Careful planning avoids deep retro-mammary vascular bundles. The gravest potential complication is pneumothorax, occurring almost exclusively when a deep lesion abuts the parietal pleura. If the needle inadvertently breaches the pleural lining, air enters the thoracic cavity. Patients present with acute chest pain and dyspnea. Preventative strategies include stringent depth control, maintaining constant sonographic visualization of the needle tip, and ensuring it remains anterior to the pleural line at all times. Management ranges from observation for minimal pneumothoraces to immediate chest tube thoracostomy for large, symptomatic collections.

An often-overlooked theoretical risk is needle-track seeding. While malignant cells could, in theory, disseminate along the puncture path, this occurrence is exceedingly rare in FNA (<0.01%) due to the fine gauge, low suction, and brief procedure time. As a precautionary measure, however, planning the needle trajectory to lie within a future surgical resection margin allows for en bloc removal of any potential implantation site during definitive surgery. Through such rigorous QC protocols and complication-mitigation strategies, the safety and diagnostic reliability of FNA are maximized.